The Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to Explode
The healthcare sector has traditionally been cautious about adopting artificial intelligence (AI), especially given the high stakes involved. Yet, AI is steadily making inroads by processing vast amounts of digital data to deliver clear, actionable insights. One of the most promising applications is optimizing drug testing and improving patient drug usage.
AI has already transformed several industries and is set to influence many more. Healthcare, however, remains somewhat reserved due to the critical importance of patient safety and the need for regulatory approval. Despite this, AI's potential to streamline drug development and patient care is gaining momentum.
Recursion Pharmaceuticals
Developing new drugs is an expensive and uncertain process. Costs can reach hundreds of millions or even over a billion dollars, with many drug candidates failing during clinical trials, particularly in phase 2. This leads to wasted time, resources, and promising therapies never reaching patients.
Recursion Pharmaceuticals (NASDAQ: RXRX) offers a solution with its Recursion OS platform. By leveraging 36 petabytes of biological and chemical data, Recursion OS can simulate drug performance in a virtual environment. This approach can predict the success or failure of drug candidates in hours and at a fraction of the cost of traditional trials.
While Recursion OS does not replace human trials—regulatory agencies still require them—it helps pharmaceutical companies prioritize drug candidates more efficiently. The platform reduces costly dead-ends, allowing firms to focus resources on the most promising options.
Recursion follows a dual business model. It develops its own drug candidates, including early-stage cancer therapies, and collaborates with established companies like Roche and Sanofi by licensing access to Recursion OS for co-development projects. Although current revenue is modest—about $34 million in the first half of this year against a net loss of $374 million—the outlook is optimistic. Analysts expect revenue to triple by 2027 and losses to shrink, moving the company toward profitability.
Tempus AI
Tempus AI (NASDAQ: TEM) takes a different approach. Its AI-driven software supports caregivers directly by simplifying complex medical data to improve patient care. This makes the technology immediately practical and market-ready.
With a market value of around $13 billion, Tempus generated $693 million in revenue last year, a 30% increase from the previous year. The company is still operating at a loss, but much of that is due to stock-based compensation and employment taxes. Continued growth could bring profitability as soon as 2027.
Tempus offers a comprehensive platform that helps diagnose hard-to-detect diseases, recommends relevant clinical trials, and predicts treatment effectiveness. Its tools are accessible not only to healthcare providers but also to patients and pharmaceutical companies like Roche and Sanofi.
The core goal is to enhance patient outcomes by making overwhelming information manageable. This practical use of AI is gaining traction among investors. Although shares have shown volatility since the June IPO, the company’s raised guidance and new product launches are encouraging signs. Analysts are gradually increasing price targets, anticipating a more consistent upward trend.
Healthcare professionals interested in AI-driven solutions might find Tempus and Recursion worth watching. Both companies carry higher-than-average risks but offer a clear vision for integrating AI into healthcare with potential long-term rewards.
For those looking to expand their knowledge in AI applications within healthcare, exploring specialized courses can be beneficial. More details can be found at Complete AI Training's healthcare courses.
Your membership also unlocks:
